Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Research

Systematic analysis of histone acetylation regulators across human cancers

Authors: Congkuan Song, Xinfei Liu, Weichen Lin, Kai Lai, Shize Pan, Zilong Lu, Donghang Li, Ning Li, Qing Geng

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

Histone acetylation (HA) is an important and common epigenetic pathway, which could be hijacked by tumor cells during carcinogenesis and cancer progression. However, the important role of HA across human cancers remains elusive.

Methods

In this study, we performed a comprehensive analysis at multiple levels, aiming to systematically describe the molecular characteristics and clinical relevance of HA regulators in more than 10000 tumor samples representing 33 cancer types.

Results

We found a highly heterogeneous genetic alteration landscape of HA regulators across different human cancer types. CNV alteration may be one of the major mechanisms leading to the expression perturbations in HA regulators. Furthermore, expression perturbations of HA regulators correlated with the activity of multiple hallmark oncogenic pathways. HA regulators were found to be potentially useful for the prognostic stratification of kidney renal clear cell carcinoma (KIRC). Additionally, we identified HDAC3 as a potential oncogene in lung adenocarcinoma (LUAD).

Conclusion

Overall, our results highlights the importance of HA regulators in cancer development, which may contribute to the development of clinical strategies for cancer treatment.
Appendix
Available only for authorised users
Literature
1.
Hanahan D. Hallmarks of Cancer: New Dimensions. CANCER DISCOV. 2022;12(1):31–46.PubMed
2.
Dai E, Zhu Z, Wahed S, Qu Z, Storkus WJ, Guo ZS. Epigenetic modulation of antitumor immunity for improved cancer immunotherapy. MOL CANCER. 2021;20(1):171.PubMedPubMedCentral
3.
Liu S, Chang W, Jin Y, Feng C, Wu S, He J, Xu T. The function of histone acetylation in cervical cancer development. Biosci Rep 2019, 39(4).
4.
Calcagno DQ, Wisnieski F, Mota E, Maia DSS, Costa DSJ, Leal MF, Gigek CO, Santos LC, Rasmussen LT, Assumpcao PP, et al. Role of histone acetylation in gastric cancer: implications of dietetic compounds and clinical perspectives. EPIGENOMICS-UK. 2019;11(3):349–62.
5.
Guo P, Chen W, Li H, Li M, Li L. The histone acetylation modifications of breast Cancer and their therapeutic implications. PATHOL ONCOL RES. 2018;24(4):807–13.PubMed
6.
Zhang L, Bu L, Hu J, Xu Z, Ruan L, Fang Y, Wang P. HDAC1 knockdown inhibits invasion and induces apoptosis in non-small cell lung cancer cells. BIOL CHEM. 2018;399(6):603–10.PubMed
7.
Darvishi N, Rahimi K, Mansouri K, Fathi F, Menbari MN, Mohammadi G, Abdi M. MiR-646 prevents proliferation and progression of human breast cancer cell lines by suppressing HDAC2 expression. Mol Cell Probes. 2020;53:101649.PubMed
8.
9.
Xu Y, Liao W, Luo Q, Yang D, Pan M. Histone Acetylation Regulator-Mediated acetylation patterns define Tumor Malignant Pathways and Tumor Microenvironment in Hepatocellular Carcinoma. FRONT IMMUNOL. 2022;13:761046.PubMedPubMedCentral
10.
Li Y, Xiao J, Bai J, Tian Y, Qu Y, Chen X, Wang Q, Li X, Zhang Y, Xu J. Molecular characterization and clinical relevance of m(6)a regulators across 33 cancer types. MOL CANCER. 2019;18(1):137.PubMedPubMedCentral
11.
Liu Z, Zhao Q, Zuo ZX, Yuan SQ, Yu K, Zhang Q, Zhang X, Sheng H, Ju HQ, Cheng H, et al. Systematic analysis of the Aberrances and functional implications of ferroptosis in Cancer. iScience. 2020;23(7):101302.PubMedPubMedCentral
12.
Landi MT, Dracheva T, Rotunno M, Figueroa JD, Liu H, Dasgupta A, Mann FE, Fukuoka J, Hames M, Bergen AW, et al. Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. PLoS ONE. 2008;3(2):e1651.PubMedPubMedCentral
13.
Selamat SA, Chung BS, Girard L, Zhang W, Zhang Y, Campan M, Siegmund KD, Koss MN, Hagen JA, Lam WL, et al. Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression. GENOME RES. 2012;22(7):1197–211.PubMedPubMedCentral
14.
Gustavsson EK, Zhang D, Reynolds RH, Garcia-Ruiz S, Ryten M. Ggtranscript: an R package for the visualization and interpretation of transcript isoforms using ggplot2. Bioinformatics. 2022;38(15):3844–6.PubMedPubMedCentral
15.
Panneerdoss S, Eedunuri VK, Yadav P, Timilsina S, Rajamanickam S, Viswanadhapalli S, Abdelfattah N, Onyeagucha BC, Cui X, Lai Z, et al. Cross-talk among writers, readers, and erasers of m(6)a regulates cancer growth and progression. SCI ADV. 2018;4(10):r8263.
16.
Barabasi AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. NAT REV GENET. 2011;12(1):56–68.PubMedPubMedCentral
17.
Kim JH, Yoon CY, Jun Y, Lee BB, Lee JE, Ha SD, Woo H, Choi A, Lee S, Jeong W, et al. NuA3 HAT antagonizes the Rpd3S and Rpd3L HDACs to optimize mRNA and lncRNA expression dynamics. NUCLEIC ACIDS RES. 2020;48(19):10753–67.PubMedPubMedCentral
18.
Werbeck ND, Shukla VK, Kunze M, Yalinca H, Pritchard RB, Siemons L, Mondal S, Greenwood S, Kirkpatrick J, Marson CM, et al. A distal regulatory region of a class I human histone deacetylase. NAT COMMUN. 2020;11(1):3841.PubMedPubMedCentral
19.
Adhikari N, Amin SA, Trivedi P, Jha T, Ghosh B. HDAC3 is a potential validated target for cancer: an overview on the benzamide-based selective HDAC3 inhibitors through comparative SAR/QSAR/QAAR approaches. EUR J MED CHEM. 2018;157:1127–42.PubMed
20.
Wang L, Zou X, Berger AD, Twiss C, Peng Y, Li Y, Chiu J, Guo H, Satagopan J, Wilton A, et al. Increased expression of histone deacetylaces (HDACs) and inhibition of prostate cancer growth and invasion by HDAC inhibitor SAHA. AM J TRANSL RES. 2009;1(1):62–71.PubMedPubMedCentral
21.
Urdinguio RG, Lopez V, Bayon GF, Diaz DLGR, Sierra MI, Garcia-Torano E, Perez RF, Garcia MG, Carella A, Pruneda PC, et al. Chromatin regulation by histone H4 acetylation at lysine 16 during cell death and differentiation in the myeloid compartment. NUCLEIC ACIDS RES. 2019;47(10):5016–37.PubMedPubMedCentral
22.
23.
Zhou HX, Pang X. Electrostatic interactions in protein structure, folding, binding, and condensation. CHEM REV. 2018;118(4):1691–741.PubMedPubMedCentral
24.
Munster PN, Marchion D, Thomas S, Egorin M, Minton S, Springett G, Lee JH, Simon G, Chiappori A, Sullivan D, et al. Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. Br J Cancer. 2009;101(7):1044–50.PubMedPubMedCentral
25.
Hess-Stumpp H. Histone deacetylase inhibitors and cancer: from cell biology to the clinic. EUR J CELL BIOL. 2005;84(2–3):109–21.PubMed
26.
Bianco-Miotto T, Chiam K, Buchanan G, Jindal S, Day TK, Thomas M, Pickering MA, O’Loughlin MA, Ryan NK, Raymond WA, et al. Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development. Cancer Epidemiol Biomarkers Prev. 2010;19(10):2611–22.PubMed
27.
Elsheikh SE, Green AR, Rakha EA, Powe DG, Ahmed RA, Collins HM, Soria D, Garibaldi JM, Paish CE, Ammar AA, et al. Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. CANCER RES. 2009;69(9):3802–9.PubMed
28.
Yao Y, Liu Q, Adrianto I, Wu X, Glassbrook J, Khalasawi N, Yin C, Yi Q, Dong Z, Geissmann F, et al. Histone deacetylase 3 controls lung alveolar macrophage development and homeostasis. NAT COMMUN. 2020;11(1):3822.PubMedPubMedCentral
29.
Topper MJ, Vaz M, Marrone KA, Brahmer JR, Baylin SB. The emerging role of epigenetic therapeutics in immuno-oncology. NAT REV CLIN ONCOL. 2020;17(2):75–90.PubMed
30.
Li X, Yu W, Qian X, Xia Y, Zheng Y, Lee JH, Li W, Lyu J, Rao G, Zhang X, et al. Nucleus-translocated ACSS2 promotes gene transcription for lysosomal Biogenesis and Autophagy. MOL CELL. 2017;66(5):684–97.PubMedPubMedCentral
31.
Wilson AJ, Byun DS, Popova N, Murray LB, L’Italien K, Sowa Y, Arango D, Velcich A, Augenlicht LH, Mariadason JM. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J BIOL CHEM. 2006;281(19):13548–58.PubMed
32.
Spurling CC, Godman CA, Noonan EJ, Rasmussen TP, Rosenberg DW, Giardina C. HDAC3 overexpression and colon cancer cell proliferation and differentiation. Mol Carcinog. 2008;47(2):137–47.PubMed
33.
Hanigan TW, Aboukhatwa SM, Taha TY, Frasor J, Petukhov PA. Divergent JNK phosphorylation of HDAC3 in Triple-Negative breast Cancer cells determines HDAC inhibitor binding and selectivity. CELL CHEM BIOL. 2017;24(11):1356–67.PubMedPubMedCentral
34.
Yang M, Dang X, Tan Y, Wang M, Li X, Li G. I-7ab inhibited the growth of TNBC cells via targeting HDAC3 and promoting the acetylation of p53. BIOMED PHARMACOTHER. 2018;99:220–6.PubMed
35.
Zhang L, Hong Z, Zhang RR, Sun XZ, Yuan YF, Hu J, Wang X. Bakkenolide A inhibits leukemia by regulation of HDAC3 and PI3K/Akt-related signaling pathways. BIOMED PHARMACOTHER. 2016;83:958–66.PubMed
36.
Mehdipour P, Santoro F, Botrugno OA, Romanenghi M, Pagliuca C, Matthews GM, Johnstone RW, Minucci S. HDAC3 activity is required for initiation of leukemogenesis in acute promyelocytic leukemia. Leukemia. 2017;31(4):995–7.PubMed
37.
Shan X, Fu YS, Aziz F, Wang XQ, Yan Q, Liu JW. Ginsenoside Rg3 inhibits melanoma cell proliferation through down-regulation of histone deacetylase 3 (HDAC3) and increase of p53 acetylation. PLoS ONE. 2014;9(12):e115401.PubMedPubMedCentral
38.
Xu G, Zhu H, Zhang M, Xu J. Histone deacetylase 3 is associated with gastric cancer cell growth via the mir-454-mediated targeting of CHD5. INT J MOL MED. 2018;41(1):155–63.PubMed
39.
Hayashi A, Horiuchi A, Kikuchi N, Hayashi T, Fuseya C, Suzuki A, Konishi I, Shiozawa T. Type-specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E-cadherin. INT J CANCER. 2010;127(6):1332–46.PubMed
40.
Zhu J, Wan H, Xue C, Jiang T, Qian C, Zhang Y. Histone deacetylase 3 implicated in the pathogenesis of children glioma by promoting glioma cell proliferation and migration. BRAIN RES. 2013;1520:15–22.PubMed
41.
42.
Yang MH, Wu MZ, Chiou SH, Chen PM, Chang SY, Liu CJ, Teng SC, Wu KJ. Direct regulation of TWIST by HIF-1alpha promotes metastasis. NAT CELL BIOL. 2008;10(3):295–305.PubMed
43.
Wu SM, Jan YJ, Tsai SC, Pan HC, Shen CC, Yang CN, Lee SH, Liu SH, Shen LW, Chiu CS et al. Targeting histone deacetylase-3 blocked epithelial-mesenchymal plasticity and metastatic dissemination in gastric cancer. CELL BIOL TOXICOL 2022.
44.
Jeong SH, Son ES, Lee YE, Kyung SY, Park JW, Kim SH. Histone deacetylase 3 promotes alveolar epithelial-mesenchymal transition and fibroblast migration under hypoxic conditions. EXP MOL MED. 2022;54(7):922–31.PubMedPubMedCentral
45.
Fangusaro J, Onar-Thomas A, Young PT, Wu S, Ligon AH, Lindeman N, Banerjee A, Packer RJ, Kilburn LB, Goldman S, et al. Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. LANCET ONCOL. 2019;20(7):1011–22.PubMedPubMedCentral
46.
Valle JW, Lamarca A, Goyal L, Barriuso J, Zhu AX. New Horizons for Precision Medicine in biliary tract cancers. CANCER DISCOV. 2017;7(9):943–62.PubMedPubMedCentral
47.
Carter CA, Rajan A, Keen C, Szabo E, Khozin S, Thomas A, Brzezniak C, Guha U, Doyle LA, Steinberg SM, et al. Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer. ANN ONCOL. 2016;27(4):693–9.PubMedPubMedCentral
Metadata
Title
Systematic analysis of histone acetylation regulators across human cancers
Authors
Congkuan Song
Xinfei Liu
Weichen Lin
Kai Lai
Shize Pan
Zilong Lu
Donghang Li
Ning Li
Qing Geng
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11220-7

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue

Research

The optimal minimum lymph node count for carcinoembryonic antigen elevated colon cancer: a population-based study in the SEER set and External set

Research

Establishment and validation of a nomogram based on coagulation parameters to predict the prognosis of pancreatic cancer

Research

Intracranial efficacy and safety of furmonertinib 160 mg with or without anti-angiogenic agent in advanced NSCLC patients with BM/LM as salvage therapy

Research

Predictive power of PEN-3 cultural model in cervical cancer screening among women: a cross- sectional study in South of Iran

Research

HELLPAR/RRM2 axis related to HMMR as novel prognostic biomarker in gliomas

Study Protocol

Randomized controlled phase III trial to investigate superiority of robot-assisted gastrectomy over laparoscopic gastrectomy for clinical stage T1-4aN0-3 gastric cancer patients (JCOG1907, MONA LISA study): a study protocol
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits